Driven by a personal connection to vision loss, Ehsan Vaghefi, CEO and co-founder of Toku, embarked on a mission to revolutionize healthcare through technology. His childhood experiences with blindness inspired him to explore the potential of ocular imaging in disease detection.
Toku's innovative platform, CLAiR, harnesses the power of AI to analyze subtle signals from retinal images, providing a non-invasive and rapid assessment of cardiovascular risks. This groundbreaking technology holds the promise of transforming routine eye exams into comprehensive cardiovascular screenings.
With its recent FDA breakthrough device designation, Toku is poised to make a significant impact on cardiovascular healthcare. The designation expedites the de novo process, paving the way for CLAiR's commercialization and widespread adoption.
Toku's vision extends beyond early detection; it envisions a future where CLAiR seamlessly integrates into routine eye exams, empowering individuals to take proactive steps towards cardiovascular health. This transformative technology has the potential to save lives and enhance the well-being of millions.
